By Denny Jacob
IGM Biosciences shares dived 69% in premarket trading a day after the company said it would halt development of two of its treatments.
Shares were trading around $1.94. The stock is up 1.5% on the year.
The biotechnology company said its decision to halt development would pertain to imvotamab and IGM-2644. It also cut its staff by 73% and is exploring internal options and strategic alternatives to maximize shareholder value while it looks to conserve cash.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
January 10, 2025 06:20 ET (11:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.